While biologics targeting IL-17 and TNF have failed to show benefit in unselected asthma populations (28, 29); perhaps only a subset of patients – e.g. those prone to severe RV-triggered exacerbations – may derive benefit from these treatment strategies. Here, IL17A is linked to asthma.